Skip to content

Mary G. Hornick

Roosevelt University

2 papers in the library · 10 citations · publishing 2023-2024

Papers

Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder

Frontiers in Pharmacology August 22, 2023 Mary G. Hornick, Ashley Stefanski 9 citations

The opioid epidemic in the United States persists, with opioid use disorder (OUD) at its core, involving physical addiction, psychological issues, and social-legal problems. Existing treatments have limited effectiveness due to access barriers, strict regimens, and failure to address non-pharmacological aspects. A growing body of research suggests hallucinogens, particularly psychoplastogens like ibogaine, ketamine, and classic psychedelics, may offer a unique, holistic alternative by combining pharmacological, neuroplasticity, and psychological mechanisms. However, legal, social, and safety concerns have hindered research. This review examines preclinical and clinical evidence for these compounds in treating OUD, while noting that further research is needed to establish long-term efficacy and proper safety and ethical guidelines.

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

Preprints.org October 17, 2024 Tamara Valdez, Valbhi Patel, Dally Senesombath et al. 1 citation preprint

Psychedelics are being reconsidered as treatments for substance use disorders (SUDs) such as alcohol and opioid use disorders, following early 20th-century anecdotal reports and pilot studies that suggested their potential. Legal restrictions and stigma had halted research, but rising rates of SUDs have renewed interest in these compounds. This review examines emerging evidence for psilocybin, ketamine, LSD, MDMA, ayahuasca, ibogaine, and peyote in treating SUDs, focusing on novel pharmacological targets and holistic approaches to improve adherence and efficacy.